Literature DB >> 16595505

Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5.

Simon M Ametamey1, Lea J Kessler, Michael Honer, Matthias T Wyss, Alfred Buck, Samuel Hintermann, Yves P Auberson, Fabrizio Gasparini, Pius A Schubiger.   

Abstract

UNLABELLED: (11)C-ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-(11)C-methyl-oxime), a noncompetitive and highly selective antagonist for the metabotropic glutamate receptor subtype 5 (mGluR5), was evaluated for its potential as a PET agent.
METHODS: ABP688 was radiolabeled with (11)C by reacting (11)C-methyl iodide with the sodium salt of desmethyl-ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime). The affinity of (11)C-ABP688 for mGluR5 was determined by Scatchard analysis using rat whole-brain membranes (without cerebellum). Ex vivo autoradiography, biodistribution, and PET studies with (11)C-ABP688 were performed on rats, wild-type mice, and mGluR5-knock-out mice.
RESULTS: The overall synthesis time was 45-50 min from the end of radionuclide production. (11)C-ABP688 was obtained in good radiochemical yield (35% +/- 8%, n = 17, decay corrected), and the specific radioactivity was 150 +/- 50 GBq/mumol (n = 17) at the end of the synthesis. Scatchard analysis revealed a single high-affinity binding site with a dissociation constant of 1.7 +/- 0.2 nmol/L and a maximum number of binding sites of 231 +/- 18 fmol/mg of protein. Ex vivo autoradiography in wild-type mice and rats showed a heterogeneous distribution pattern consistent with the known distribution of mGluR5 in the brain, with the highest uptake in hippocampus, striatum, and cortex. Blocking studies by coinjection of (11)C-ABP688 and unlabeled 2-methyl-6-(3-methoxyphenyl)ethynyl-pyridine (1 mg/kg), an antagonist for mGluR5, revealed up to 80% specific binding in rat brain. In mGluR5-knock-out mouse brain, a homogeneous and markedly reduced accumulation of (11)C-ABP688 was observed. PET studies on rats and mice using a small-animal PET scanner also demonstrated radioactivity uptake in the brain regions known to be rich in mGluR5. In contrast, radioactivity uptake in mGluR5-knock-out mice was fairly uniform, substantiating the specificity of (11)C-ABP688 binding to mGluR5.
CONCLUSION: (11)C-ABP688 is a selective tracer for imaging mGluR5 in vivo in rodents and may offer a future tool for imaging mGluR5 in humans using PET.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16595505

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  61 in total

1.  In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688.

Authors:  David Elmenhorst; Luciano Minuzzi; Antonio Aliaga; Jared Rowley; Gassan Massarweh; Mirko Diksic; Andreas Bauer; Pedro Rosa-Neto
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-09       Impact factor: 6.200

2.  In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.

Authors:  Christine DeLorenzo; Matthew S Milak; Kathleen G Brennan; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

Review 3.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Comparative assessment of parametric neuroreceptor mapping approaches based on the simplified reference tissue model using [¹¹C]ABP688 PET.

Authors:  Seongho Seo; Su J Kim; Yu K Kim; Jee-Young Lee; Jae M Jeong; Dong S Lee; Jae S Lee
Journal:  J Cereb Blood Flow Metab       Date:  2015-08-05       Impact factor: 6.200

5.  Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study.

Authors:  Alexandra Deschwanden; Beata Karolewicz; Anteneh M Feyissa; Valerie Treyer; Simon M Ametamey; Anass Johayem; Cyrill Burger; Yves P Auberson; Judit Sovago; Craig A Stockmeier; Alfred Buck; Gregor Hasler
Journal:  Am J Psychiatry       Date:  2011-04-15       Impact factor: 18.112

6.  Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system.

Authors:  Masaki Tokunaga; Nicholas Seneca; Ryong-Moon Shin; Jun Maeda; Shigeru Obayashi; Takashi Okauchi; Yuji Nagai; Ming-Rong Zhang; Ryuji Nakao; Hiroshi Ito; Robert B Innis; Christer Halldin; Kazutoshi Suzuki; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 7.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

8.  Studies of the metabotropic glutamate receptor 5 radioligand [¹¹C]ABP688 with N-acetylcysteine challenge in rhesus monkeys.

Authors:  Christine M Sandiego; Nabeel Nabulsi; Shu-Fei Lin; David Labaree; Soheila Najafzadeh; Yiyun Huang; Kelly Cosgrove; Richard E Carson
Journal:  Synapse       Date:  2013-03-27       Impact factor: 2.562

9.  Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography.

Authors:  Funda Akkus; Simon M Ametamey; Valerie Treyer; Cyrill Burger; Anass Johayem; Daniel Umbricht; Baltazar Gomez Mancilla; Judit Sovago; Alfred Buck; Gregor Hasler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

10.  Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11 C]ABP688 PET imaging.

Authors:  William B Mathews; Hiroto Kuwabara; Kirstie Stansfield; Heather Valentine; Mohab Alexander; Anil Kumar; John Hilton; Robert F Dannals; Dean F Wong; Fabrizio Gasparini
Journal:  Synapse       Date:  2014-08-19       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.